PEOPLE

armonia
sad
Luca Rovati
Vice Chairman
sad
Francesco Chiappetta
Vice Chairman
sad
Alessandro Grimaldi
Chief Executive Officer
sad
Dario Cenci
Partner
petrone
Raffaele Petrone
Jr Partner
sad
Chiara Bernini
Associate
sad
Stefano Manghi
Associate
diaz
Luca Rovati Vice Chairman
TRACK RECORD
BIOGRAPHY

  • Vice Chairman of MEDA AB and second shareholder of MEDA Group.
  • Since June 2013, he has been BoD member of Nuove Partecipazioni S.p.A., through which he owns 50% of Nuova Camfin S.p.A. and, indirectly 26% of Pirelli & C. S.p.A.
  • Before closing the successful sale to MEDA AB (2014), Rovati served as Executive Vice Chairman of Rottapharm Group where, supported by Diaz Pallavicini, he managed several M&A deals.
  • He has also been lecturer at Finafrica Foundation, Università Cattolica del Sacro Cuore in Milan and Università Bocconi in Milan.

SAUGELLA

  • Target
    - Laboratori Guieu is a company operating in the dermocosmetics sector with a turnover of approx. 30mn€ mainly coming from two brands: Saugella e Babygella.
  • Deal
    - In 1999, Rottapharm Group acquires 100% of Laboratori Guieu from Bristol Myers Squibb.
  • Actions Taken
    - Entrance in the dermocosmetics sector.
    - Introduction of Saugella and Babygella brands on foreign markets.
    - Consolidation of the growth process undertaken by Rottapharm Group.

BIOCHIMICI PSN

  • Target
    - Biochimici PSN is a company specialized in developing and selling dermatological products with a turnover of approx. 28mn€ (2005), a range of over 100 different products and an established position on the market.
  • Deal
    - In 2005, Rottapharm Group acquires 100% of the Biochimici PSN from Athena and Fidia Prudentia Funds.
  • Actions Taken
    - Products range expansion in dermatological, hair-care and sun-screen areas.
    - Leadership achievement in the Personal Care area.
    - Consolidation of the para-pharmacy sector and further consolidation of Group growth process started in 2000 with the acquisition of Saugella and Babygella.

MADAUS PHARMA

  • Target
    - Madaus Pharma is one of the main companies in the pharmaceutical sector specialized in developing and selling organic pharmaceutical products.
  • Deal
    - In 2007, Rottapharm Group acquires, from Droege International Group AG, 100% of Madaus Pharma, the pharmaceutical department of Madaus Holding.
  • Actions Taken
    - Most important M&A deal made by an Italian company in the pharmaceutical sector.
    - Presence strengthening in Germany, Spain and Portugal (leading pharmaceutical company) and entrance in new countries such as Belgium,Austria, South Africa and India.
    - Creation of a Group operating in more than 65 countries and with more than 2,000 employees.

RHOTTAPHARM

  • Target
    - The Rottapharm|Group was founded in 1961 by the Rovati family.
    - Founded as a little independent laboratory of research, during the following decades thanks to several successful M&A deals, it becomes a Group with a turnover of 535mln€ and an EBITDA of 149mln€ (2013).
  • Deal
    - In 2014 Meda AB acquires 100% of Rottapharm|Madaus for a total consideration of 2.275bn€.
    - R&D activities dedicated to high technology medicines, have been excluded from the transaction.
  • Actions Taken
    - Creation of a European Group leader in the Specialty Pharma sector, focused on specific therapeutic areas and market niches.
    - Unique portfolio products in the world in terms of diversification and market positioning.
    - Stable presence in all main international markets, especially in emergent markets with higher growth potential.